Daytona Beach, FLNCT07523711Now EnrollingIRB Ready

Overweight Clinical Trial in Daytona Beach, FL

Access cutting-edge overweight treatment through this clinical trial at a research site in Daytona Beach. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Daytona Beach location

Preparing your pre-screening questions…

Expert Care in Daytona Beach

Access overweight specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related overweight treatment provided free

Apply for This Daytona Beach Location

Check if you qualify for this overweight clinical trial in Daytona Beach, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Daytona Beach

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Daytona Beach site if eligible
  4. 4Begin participation

About This Overweight Study in Daytona Beach

The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Participants must be postmenopausal females 45 to 65 years of age. Postmenopausal status must be confirmed based on the protocol-defined criteria.
Body mass index must be ≥ 25.0 and ≤ 38.0 kg/m\^2.
Body weight must be stable, with less than 5 kg self-reported change in the 3 months before screening.
Participants must not have changed their diet or started a nutritional lifestyle modification program within 3 months before screening.
Other inclusion criteria may apply.

Exclusion Criteria

History or evidence of any clinically significant medical condition, abnormal physical exam, ECG, vital sign, or laboratory finding that could increase risk or interfere with study participation.
History of diabetes, active diabetes, or hemoglobin A1c 6.5% or higher.
Endocrine disorders that can cause obesity, such as Cushing's syndrome.
History of acute or chronic pancreatitis within 1 year before check-in, pancreatic enzyme elevations greater than 2 times the upper limit of normal, or fasting triglycerides greater than 300 mg/dL.
Bleeding or clotting disorders, abnormal coagulation tests, or a history of venous or arterial blood clots or conditions that increase clot risk.
LDL cholesterol greater than 159 mg/dL.
Migraine with aura, normal pressure hydrocephalus, or ischemic optic neuropathy.
Malignancy within the past 5 years, except nonmelanoma skin cancer.
Unexplained postmenopausal vaginal bleeding, untreated endometrial disease, or other gynecologic conditions that could worsen with estrogen/progestin therapy.
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or uncontrolled thyroid disease.
Gastroparesis, inability to swallow oral medication, clinically important gastrointestinal disease, malabsorption, uncontrolled inflammatory bowel disease, certain gastrointestinal surgeries, or recent bariatric surgery.
Clinically significant cardiovascular disease, clinically significant arrhythmia, long QT syndrome, QTcF greater than 470 msec, second- or third-degree atrioventricular block, or clinically important abnormal pulse rate or systolic blood pressure \> 150 mmHg or \< 90 mmHg, diastolic blood pressure \> 95 mmHg or \< 50 mmHg.
Allergy, hypersensitivity, intolerance, or contraindication to maridebart cafraglutide, ethinyl estradiol, or orgestimate.
Reduced kidney function with estimated glomerular filtration rate 60 mL/min/1.73 m\^2 or lower, ALT or AST greater than 2 times the upper limit of normal, or a history of acute or chronic liver disease, hepatic adenoma, or hepatic carcinoma.
Hemoglobin or hematocrit below the lower limit of normal.
Positive HIV test, or positive hepatitis B surface antigen or hepatitis C antibody at screening.
Lifetime history of suicide attempt, non-suicidal self-injury within 5 years, or unstable major depressive disorder or other severe psychiatric disorder within 2 years.
Positive pregnancy test at screening or check-in.
Recent use of medications that could affect study participation, including most prescription or over-the-counter medications, systemic hormone replacement therapy, certain contraceptive hormones, CYP enzyme inducers or inhibitors, GLP-1 receptor or GIP receptor agents, and nonpermitted herbal products, vitamins, or supplements.
Recent participation in another investigational study, prior participation in this study, or prior exposure to maridebart cafraglutide.
Tobacco or nicotine use within 3 months before check-in, positive cotinine test, history of alcoholism or drug abuse, positive alcohol or illicit drug testing, recent illicit drug use, or unwillingness to avoid illicit drugs or cannabinoids during the study.
Recent blood, plasma, or platelet donation.
Other exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Daytona Beach?

Yes, this clinical trial (NCT07523711) has an active research site in Daytona Beach, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Overweight Treatment Options in Daytona Beach, FL

If you're searching for overweight treatment options in Daytona Beach, FL, this clinical trial (NCT07523711) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Daytona Beach research site is actively enrolling participants for this clinical trial. You'll receive care from experienced overweight specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all overweight clinical trials near you to find additional studies recruiting in your area.

More Obesity Trials in Daytona Beach, FL

See all obesity clinical trials recruiting in Daytona Beach — not just this study.

Browse Obesity Trials in Daytona Beach →

Browse More Trials by Condition

Obesity TrialsAll Conditions →

Ready to Join in Daytona Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Daytona Beach, FL